Abstract

BackgroundThe last decade has seen a major increase in the availability of genomic data. This includes expert-curated databases that describe the biological activity of genes, as well as high-throughput assays that measure gene expression in bulk tissue and single cells. Integrating these heterogeneous data sources can generate new hypotheses about biological systems. Our primary objective is to combine population-level drug-response data with patient-level single-cell expression data to predict how any gene will respond to any drug for any patient.MethodsWe take 2 approaches to benchmarking a “dual-channel” random walk with restart (RWR) for data integration. First, we evaluate how well RWR can predict known gene functions from single-cell gene co-expression networks. Second, we evaluate how well RWR can predict known drug responses from individual cell networks. We then present two exploratory applications. In the first application, we combine the Gene Ontology database with glioblastoma single cells from 5 individual patients to identify genes whose functions differ between cancers. In the second application, we combine the LINCS drug-response database with the same glioblastoma data to identify genes that may exhibit patient-specific drug responses.ConclusionsOur manuscript introduces two innovations to the integration of heterogeneous biological data. First, we use a “dual-channel” method to predict up-regulation and down-regulation separately. Second, we use individualized single-cell gene co-expression networks to make personalized predictions. These innovations let us predict gene function and drug response for individual patients. Taken together, our work shows promise that single-cell co-expression data could be combined in heterogeneous information networks to facilitate precision medicine.

Highlights

  • Advances in high-throughput RNA-sequencing (RNA-Seq) have made it possible to quantify RNA presence in any biological sample [1], producing a gene expression signature that can serve as a biomarker for disease prediction [2,3,4] or surveillance [5, 6]

  • Our work shows promise that singlecell co-expression data could be combined in heterogeneous information networks to facilitate precision medicine

  • random walk with restart (RWR) can handle sparse heterogeneous data, the positive and negative information obtained for each node can be infinitesimally small

Read more

Summary

Introduction

Advances in high-throughput RNA-sequencing (RNA-Seq) have made it possible to quantify RNA presence in any biological sample [1], producing a gene expression signature that can serve as a biomarker for disease prediction [2,3,4] or surveillance [5, 6]. Compared with conventional bulk RNA-Seq, which measures the average gene expression for an individual sample, single-cell RNA-Seq (scRNA-Seq) measures gene expression for an individual cell This new mode of data makes it possible to explore tissue heterogeneity, notably tumor heterogeneity [8], by producing multiple data points per individual (i.e., one for each cell). The last decade has seen a major increase in the availability of genomic data This includes expert-curated databases that describe the biological activity of genes, as well as high-throughput assays that measure gene expression in bulk tissue and single cells. Integrating these heterogeneous data sources can generate new hypotheses about biological systems. Our primary objective is to combine population-level drug-response data with patient-level single-cell expression data to predict how any gene will respond to any drug for any patient

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.